Polymer Expertise Meets AI-Guided Experimentation
The collaboration combines Corbion's PURASORB® polymer portfolio with Intrepid Labs' automated experimentation and AI capabilities. Its broader approach was presented at the Controlled Release Society's 2026 meeting, emphasizing interactions between polymer properties, formulation composition, and manufacturing processes. For development teams, this integrated perspective matters because choosing a polymer is only one part of establishing a workable injectable formulation. A practical research programme must connect material selection with preparation conditions and measurable product performance. The collaboration illustrates how polymer suppliers and formulation specialists can organize these decisions around a shared set of development requirements.
Experimental Screening Explores 181 Formulations
Over approximately 15 weeks, the researchers prepared and characterized 181 unique formulations with drug loadings ranging from 6% to 12% by weight. These were formulations for one therapeutic peptide, rather than 181 different peptides. The campaign provides a useful example of how experimental breadth can support formulation decisions. For researchers assessing a similar workflow, the important questions would include whether the tested combinations adequately represent the intended design space and whether measurements are reproducible. Recording unsuccessful formulations alongside promising ones would also help identify practical boundaries and guide subsequent experiments toward combinations with a stronger development rationale.
Four Candidates Offer Distinct Release Profiles
Four lead formulations were identified across drug loadings of 6%, 9%, and 12% by weight. Each met the study's predefined viscosity and injectability criteria while producing a distinct 30-day in vitro release profile. This outcome provides several options for further evaluation rather than establishing a single universally optimal system. Candidate selection would depend on the intended dose, acceptable injection volume, and desired release trajectory. Importantly, a 30-day laboratory release profile does not establish one-month exposure or efficacy in patients. Follow-up work would need to examine how the selected formulations behave under relevant biological conditions.
Optimization Addresses Release and Injection Trade-Offs
The study found that intermediate-molecular-weight polymers offered a favorable balance between sustained release and solution viscosity within the evaluated formulation space. This finding highlights the need to assess coupled properties during candidate development. For example, a formulation that appears attractive because of its release behavior may still require changes if preparation or injection performance is unsuitable. A practical assessment would compare these attributes under consistent conditions and document which compromises remain acceptable. Such analysis can help teams select candidates with an overall workable profile, while avoiding the assumption that a favorable polymer choice will transfer unchanged to another peptide.
Further Development Will Test Robustness and Biological Performance
The reported candidates provide a foundation for further optimization and in vivo evaluation, according to the researchers. A subsequent development programme could investigate peptide integrity, storage stability, reproducibility of depot formation, and sensitivity to manufacturing variation. Biological studies would then be needed to assess exposure, local tolerability, and the relationship between laboratory release measurements and in vivo performance. Scale-up and product presentation would require separate consideration, including preparation procedures and delivery consistency. Together, these steps would determine whether the shortlisted systems can progress from promising experimental formulations toward a robust long-acting injectable product.
